Skip Navigation

Annals of Oncology 2005 16(Supplement 4):iv90-iv94; doi:10.1093/annonc/mdi915
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by De Giorgi, U.
Right arrow Articles by Marangolo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Giorgi, U.
Right arrow Articles by Marangolo, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Invited Paper

FDG-PET in the management of germ cell tumor

U. De Giorgi1,*, A. Pupi2, G. Fiorentini1, G. Rosti3 and M. Marangolo3

1 Istituto Toscano Tumori, Department of Oncology, San Giuseppe Hospital, Empoli Florence, Italy; 2 Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy; 3 Istituto Oncologico Romagnolo, Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Ravenna, Italy

* Correspondence to: Dr Ugo De Giorgi, Istituto Toscano Tumori, Department of Oncology, San Giuseppe Hospital, Via Paladini 40, 50053 Empoli, Florence, Italy. Tel: +39-0571-702605; Fax: +39-0571-702671; Email: ugo_degiorgi{at}yahoo.com

Germ cell tumor is the most common malignancy in young men. The cure rate of these patients has tremendously increased in the cisplatin era, and recent results have indicated that the management of patients with GCT is still improving. The use of FDG-PET in the management of patients with GCT has been recently investigated. This report attempts to comprehensively review new advances and delineate the potential applications of FDG-PET in GCT.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.